Scientists NMITs them. VA Almazova, St. Petersburg Electrotechnical University “LETI” conducted successful preclinical studies of a new drug for the treatment and treatment of pulmonary vessels clogged with blood clots. About this “socialbites.ca” St. Petersburg Electrotechnical University “LETI”.
Acute obstruction of parts of the circulatory system by a thrombus or its fragment is called thromboembolism. This disease is most dangerous in the lungs.
A fragment of a thrombus clogs the pulmonary artery, which causes pulmonary hypertension and increased load on the right ventricle of the heart, which is dangerous for the development of heart failure.
In response to the blockage of blood vessels, the Janus kinase enzyme initiates the body’s defense processes. They aim to dissolve the thrombus and relieve congestion, but the vessels contract and swell. This causes serious discomfort that can be fatal to the patient in a short time.
To prevent such a reaction of the body, scientists suggested using an inhibitor (suppressor) of Janus kinase.
“The inhibitor blocks the action of enzymes that help stimulate inflammation in the immune system and is commonly used in the treatment of rheumatoid arthritis. However, the results of preclinical studies show its effectiveness in combating pulmonary hypertension. It blocks the body’s protective reaction, allowing you to relieve symptoms, save pulmonary vessels, and ultimately allows you to extend the life of the patient, ”said the head of the National Research Laboratory of Pulmonary Circulatory Pathology. Medical Research Center named after AI. VA Almazova Andrey Karpov.
Preclinical studies of the drug were carried out on laboratory mice: scientists injected them with a medicinal substance, and then took about 2,000 microphotographs of the pulmonary arteries of rodents in the episode. For efficient and automated analysis of images, doctors have been working on St. He used a special program “LETI”, developed by scientists from St. Petersburg Electrotechnical University.
“Our application made it possible to increase the speed of analysis of micrographs collected during preclinical trials of a new drug for the treatment of pulmonary hypertension caused by thromboembolism in the lungs by 4 times,” said Ksenia Sanarova, the developer of the program. Interview with socialbites.ca.
Now a group of researchers is preparing to conduct clinical trials of the drug. The scientists’ ultimate goal is to bring it to market as a treatment for pulmonary hypertension.